Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p31
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 31/31)
Character Range: 105515–106873

for Filgrastim in the form Injection 480 micrograms in 0.5 mL single-use pre-filled syringe [GRP-23385]
     omit from the column headed "Brand": Neupogen

     [125]           Schedule 5, after entry for Glucagon in the form Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe (s19A) [GRP-27816]
     insert:
Hydromorphone  GRP-28212  Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL       Oral  Hikma
                          Oral solution containing hydromorphone hydrochloride 1mg per mL, 1mL (S19A)  Oral  Hydromorphone hydrochloride oral solution, USP (Medsurge)

     [126]           Schedule 5, entry for Olanzapine in the form Tablet 5 mg (orally disintegrating) [GRP-15797]
     omit from the column headed "Brand": Olanzapine ODT generichealth 5

     [127]           Schedule 5, entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg [GRP-15402]
     omit from the column headed "Brand": APO-Ondansetron ODT

     [128]           Schedule 5, entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg [GRP-15983]
     omit from the column headed "Brand": APO-Ondansetron ODT

     [129]           Schedule 5, entry for Ramipril in the form Tablet 1.25 mg [GRP-15640]
     insert in alphabetical order in the column headed "Brand": Ramipril Viatris